On Tuesday, BofA Securities maintained a positive stance on Teva Pharmaceutical Industries Limited (NYSE:TEVA), reiterating a Buy rating and a $23.00 price target for the company's stock. Currently trading at $16.65 with a market capitalization of $18.8 billion, Teva has demonstrated strong momentum with a 59% gain year-to-date.
The endorsement comes after a detailed review of the company's potential product developments expected by 2025. The analysis suggests that Teva is on track to achieve another year of robust revenue and EBITDA growth at a mid-single-digit percentage rate.
The firm's assessment indicates that while they do not anticipate significant beats on 2025 consensus estimates, Teva's solid execution is crucial for reaching its long-term financial goals set for 2027. These targets are projected to offer a low-double-digit percentage upside to BofA's consensus EBITDA estimates, which currently stands at $4.8 billion.
According to InvestingPro analysis, the company shows promising signs with strong free cash flow yield and impressive revenue growth of 9.8% over the last twelve months.
BofA Securities highlighted the encouraging trends in the utilization of Teva's products, such as Uzedy, Austedo, and its biosimilars. These trends are expected to contribute to the company's performance in 2025 and potentially lead to upward revisions in estimates. Such revisions would be necessary to balance out the anticipated decline in growth due to the generic competition for Revlimid, which is expected to intensify after 2026.
InvestingPro data reveals that analysts maintain a bullish stance, with price targets ranging from $18 to $26, suggesting potential upside from current levels. Get access to 8 more exclusive ProTips and comprehensive analysis through InvestingPro's detailed research reports.
The firm has adjusted its 2025 estimates for Teva, taking into account a lower multiple for the sector. Despite this adjustment, BofA Securities reaffirms its Buy rating, suggesting that Teva's stock could be re-rated to reflect a pharmaceutical growth multiple. This outlook is based on the company's current performance and expected developments over the next few years.
In other recent news, Teva Pharmaceuticals reported a 15% increase in Q3 2024 revenues, reaching $4.3 billion. This growth was driven by the success of its innovative products such as AUSTEDO, AJOVY, and UZEDY, and its generics segment, which saw a 17% global increase. Despite a GAAP net loss due to goodwill impairment and legal settlements, Teva's adjusted EBITDA and EPS showed significant improvement.
The company is making strategic moves, including pipeline developments and effective debt management, which has led to credit rating upgrades from S&P, Fitch, and Moody's (NYSE:MCO). Teva's net debt has been reduced to $15.7 billion. In addition, the company has raised its full-year revenue guidance to between $16.1 billion and $16.5 billion.
Teva is expanding its biosimilar portfolio with 17 products in development, including a key biosimilar for Prolia. Clinical trials are progressing in areas such as ulcerative colitis, Crohn's disease, celiac disease, and vitiligo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.